Clinical Trials Browser

Phase 2 × Lung Neoplasms × HMPL-013 × Clear all

NCT03684967 2019-11-19

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Phase 2 Withdrawn

Lung Neoplasms